Format

Send to

Choose Destination
See comment in PubMed Commons below
Diab Vasc Dis Res. 2013 Sep;10(5):397-409. doi: 10.1177/1479164113490765. Epub 2013 May 27.

Individualized glycaemic targets and pharmacotherapy in type 2 diabetes.

Author information

1
Diabetes Research, School of Life & Health Sciences, Aston University, Birmingham, UK. c.j.bailey@aston.ac.uk

Abstract

The Global Partnership for Effective Diabetes Management, established to provide practical guidance to improve patient outcomes in diabetes, has developed and modified recommendations to improve glycaemic control in type 2 diabetes. The Global Partnership advocates an individualized therapeutic approach and, as part of the process to customize therapy, has previously identified specific type 2 diabetes patient subgroups that require special consideration. This article builds on earlier publications, expanding the scope of practical guidance to include newly diagnosed individuals with complications and women with diabetes in pregnancy. Good glycaemic control remains the cornerstone of managing type 2 diabetes, and plays a vital role in preventing or delaying the onset and progression of diabetic complications. Individualizing therapeutic goals and treatments to meet glycaemic targets safely and without delay remains paramount, in addition to a wider programme of care to reduce cardiovascular risk factors and improve patient outcomes.

KEYWORDS:

Global Partnership; Glycaemic targets; HbA1c; individualized therapy; type 2 diabetes

PMID:
23711582
DOI:
10.1177/1479164113490765
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center